Antithrombin III, Human Plasma recombinant protein
SERPINC1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P01008 |
---|---|
Calculated MW | 58 kDa |
Gene ID | 462 |
---|---|
Gene Symbol | SERPINC1 |
Other Names | SERPINC1 |
Gene Source | Human |
Source | Human Plasma |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | N/A; |
Recombinant | No |
Target/Specificity | Antithrombin III |
Application Notes | In water or aqueous buffer |
Format | Lyophilized |
Storage | -20°C; Lyophilized from 50 mM Tris-HCl, pH 8.0, with 150 mM NaCl. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SerpinC1, also known as antithrombin III (AT III), is a member of the serpin superfamily of serine protease inhibitors, and has been found to be a marker for disseminated intravascular coagulation (DIC) and to be of prognostic significance in septic patients. SerpinC1 synthesized in the liver is the principal plasma serpin of blood coagulation proteases and inhibits thrombin and other factors such as Xa by the formation of covalently linked complexes. Thus it is one of the most important coagulation inhibitors and the fundamental enzyme for the therapeutical action of heparin. In common with SerpinA5 and D1, the inhibitory activity of SerpinC1 undergoes a dramatic increase in the presence of heparin and other glycosaminoglycans. ATIII mediates the promotion of prostaglandin release, an inhibitor of leucocyte activation and downregulator of many proinflammatory cytokines. Antithrombin III exerts anti-inflammatory properties in addition to its anti-coagulative mechanisms. In animal models of sepsis, ATIII affected cytokine plasma concentrations with a decrease of pro-inflammatory cytokines. The deficiency or functional abnormality of ATIII may result in an increased risk of thromboembolic disease, such as deep vein thrombosis and pulmonary embolism. In addition, it has been reported that SerpinC1 can alter or influence inflammatory processes via inhibition of NF-κB activation or actin polymerization. Antithrombin III is found in normal serum at 15 mg per 100 ml. Found at higher levels in plasma than in serum because of complexing with thrombin during coagulation. Clinically, reduced levels are indicative of hypercoagulability.
References
Bock S.C.,et al.Nucleic Acids Res. 10:8113-8125(1982).
Chandra T.,et al.Proc. Natl. Acad. Sci. U.S.A. 80:1845-1848(1983).
Tsuji H.,et al.(In) Yoshida T.O., Wilson J.M. (eds.);
Olds R.J.,et al.Biochemistry 32:4216-4224(1993).
Zhang C.,et al.Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.